GlassScriptPhysician profile
James Pfister
NPI 1578628558
$3,597.33
in general payments reported to CMS, 2019-2025
28 companies · $743 in 2025
The $743 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $887 · 2020: $313 · 2021: $377 · 2022: $327 · 2023: $335 · 2024: $614 · 2025: $743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,692.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,174.48 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $611.68 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $250.00 | 2019 | |
| Lilly USA, LLC | $212.26 | 2021-2025 | Zepbound, Jardiance, Mounjaro |
| Novo Nordisk INC | $172.06 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $159.20 | 2019 | |
| Merck Sharp & Dohme LLC | $150.44 | 2019-2023 | Belsomra |
| Glaxosmithkline, LLC. | $71.98 | 2020-2025 | Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.88 | 2020-2025 | Xifaxan, Trulance |
| Biohaven Pharmaceutical Holding Company LTD. | $64.04 | 2022 | |
| Arbor Pharmaceuticals, INC. | $63.68 | 2019-2022 | |
| Corium, LLC | $62.46 | 2023-2024 | Azstarys, Azstarys |
| Jazz Pharmaceuticals INC. | $57.75 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $56.34 | 2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.70 | 2019-2023 | Jardiance |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $44.46 | 2023-2024 | Quviviq |
| Eisai INC. | $41.66 | 2019-2020 | |
| Exact Sciences Corporation | $33.76 | 2025 | Cologuard Collection Kit |
| Azurity Pharmaceuticals, INC. | $31.54 | 2023 | Edarbi |
| Gilead Sciences, INC. | $30.61 | 2019 | |
| Astellas Pharma US INC | $30.42 | 2019-2022 | |
| Tris Pharma INC | $30.26 | 2023 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $25.48 | 2019-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $24.54 | 2022 | |
| Phathom Pharmaceuticals, INC. | $23.14 | 2024 | Voquezna |
| Amgen INC. | $17.61 | 2025 | Evenity |
| Amarin Pharma, INC. | $16.51 | 2019 | |
| Pfizer INC. | $15.39 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Pfister listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.